1015 Chestnut Street
Suite 1020
Philadelphia, PA 19107
(215) 955-7785
(215) 955-9362 fax
Suite 1020
Philadelphia, PA 19107
(215) 955-7785
(215) 955-9362 fax
Most Recent Peer-reviewed Publications
- Inflammatory biomarker changes and their correlation with framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES
- Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination.
- Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination
- Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-Week outcomes from GRACE
- Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women
- Gender-sensitive reporting in medical research
- Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women
- ARIES 144 week results: Durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine
- Health-related quality of life in the gender, race, and clinical experience trial
- Prevalence of obstructive lung disease in HIV population: A cross sectional study
- Recruitment and retention of diverse populations in antiretroviral clinical trials: Practical applications from the Gender, Race and Clinical Experience study
- Health needs of HIV-infected women in the United States: Insights from the women living positive survey
- Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
- Letter in response to the new SHEA guideline for healthcare workers with hepatitis B Virus, hepatitis C virus, and/or human immunodeficiency virus
- Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus
- Sex-based outc 081F omes of Darunavir-Ritonavir therapy: A single-group trial
- Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients
- A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen
- Integrase inhibitors: A novel class of antiretroviral agents
- Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients